NCT04429191View on ClinicalTrials.gov

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 8, 2020

Primary Completion Date

October 15, 2023

Study Completion Date

December 8, 2023

Conditions
MYELODYSPLASTIC SYNDROME; MDSACUTE MYELOID LEUKEMIA; AML
Interventions
BIOLOGICAL

Humanized anti-CD117 Monoclonal Antibody (JSP191)

Procedure: single intravenous infusion of JSP191 antibody

Trial Locations (6)

60612

RECRUITING

Rush University Medical Center, Chicago

84112

RECRUITING

Huntsman Cancer Institute - University of Utah, Salt Lake City

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

94305

RECRUITING

Stanford University, Stanford

97239

RECRUITING

Oregon Health & Science University, Portland

98109

RECRUITING

Fred Hutchinson Cancer Research Center, Seattle

Sponsors
All Listed Sponsors
lead

Jasper Therapeutics, Inc.

INDUSTRY